Inflammatory characteristics
| Inflammatory characteristics | N=35 | % |
| Tumor PD-L1 expression | ||
| Positive | 3 | 8.6 |
| Negative | 17 | 48.6 |
| Missing | 15 | 42.9 |
| Median | Range | |
| CD3+TILs/mm2 tumor | 188.51 | 5.4–1060.14 |
| CD8+TILs/mm2 tumor | 96.0 | 4.12–944.88 |
| CD45RO+TILs/mm2 tumor | 39.47 | 1.3–531.41 |
| FOXP3+TILs/mm2 tumor | 24.62 | 0.60–608.52 |
| PD-1+TILs/mm2 tumor | 12.20 | 0.13–622.13 |
| LAG3+TILs/mm2 tumor | 29.41 | 1.22–1083.54 |
| NLR (missing n=4) | 4.03 | 1.53–18.25 |
| LLR (missing n=4) | 6.07 | 2.94–23.63 |
| PLR (missing n=4) | 247.50 | 128.75–1516.95 |
| MLR (missing n=4) | 0.54 | 0.22–4.25 |
AEs, adverse events; CD, cluster of differentiation; FOXP3, forkhead box protein P3; LAG3, lymphocyte-activation gene 3; LLR, leucocyte-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio; PD-L1, programmed death ligand 1; PLR, platelet-to-lymphocyte ratio; TILs, tumor-infiltrating lymphocytes.